Publication

Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge

Tomar, J., Patil, H. P., Bracho, G., Tonnis, W. F., Frijlink, H. W., Petrovsky, N., Vanbever, R., Huckriede, A. & Hinrichs, W. L. J., 28-Oct-2018, In : Journal of Controlled Release. 288, p. 199-211 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Tomar, J., Patil, H. P., Bracho, G., Tonnis, W. F., Frijlink, H. W., Petrovsky, N., ... Hinrichs, W. L. J. (2018). Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. Journal of Controlled Release, 288, 199-211. https://doi.org/10.1016/j.jconrel.2018.09.006

Author

Tomar, Jasmine ; Patil, Harshad P. ; Bracho, Gustavo ; Tonnis, Wouter F. ; Frijlink, Henderik W. ; Petrovsky, Nikolai ; Vanbever, Rita ; Huckriede, Anke ; Hinrichs, Wouter L. J. / Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. In: Journal of Controlled Release. 2018 ; Vol. 288. pp. 199-211.

Harvard

Tomar, J, Patil, HP, Bracho, G, Tonnis, WF, Frijlink, HW, Petrovsky, N, Vanbever, R, Huckriede, A & Hinrichs, WLJ 2018, 'Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge' Journal of Controlled Release, vol. 288, pp. 199-211. https://doi.org/10.1016/j.jconrel.2018.09.006

Standard

Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. / Tomar, Jasmine; Patil, Harshad P.; Bracho, Gustavo; Tonnis, Wouter F.; Frijlink, Henderik W.; Petrovsky, Nikolai; Vanbever, Rita; Huckriede, Anke; Hinrichs, Wouter L. J.

In: Journal of Controlled Release, Vol. 288, 28.10.2018, p. 199-211.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Tomar J, Patil HP, Bracho G, Tonnis WF, Frijlink HW, Petrovsky N et al. Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. Journal of Controlled Release. 2018 Oct 28;288:199-211. https://doi.org/10.1016/j.jconrel.2018.09.006


BibTeX

@article{cbcddc8d97644be881f3962e49c1e6c0,
title = "Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge",
abstract = "Administration of influenza vaccines via the respiratory tract has potential benefits over conventional parenteral administration, inducing immunity directly at the site of influenza exposure as well as being needle free. In this study, we investigated the suitability of Advax (TM), a stable particulate polymorph of inulin, also referred to as delta inulin, as a mucosal adjuvant for whole inactivated influenza vaccine (WIV) administered either as a liquid or dry powder formulation. Spray freeze-drying produced Advax-adjuvanted WIV powder particles in a size range (1-5 mu m) suitable for inhalation. The physical and biological characteristics of both WIV and Advax remained unaltered both by admixing WIV with Advax and by spray freeze drying. Upon intranasal or pulmonary immunization, both liquid and dry powder formulations containing Advax induced significantly higher systemic, mucosal and cellular immune responses than non-adjuvanted WIV formulations. Furthermore, pulmonary immunization with Advax-adjuvanted WIV led to robust memory B cell responses along with an increase of lung localization factors i.e. CXCR3, CD69, and CD103. A less pronounced but still positive effect of Advax was seen on memory T cell responses. In contrast to animals immunized with WIV alone, all animals pulmonary immunized with a single dose of Advax-adjuvanted WIV were fully protected with no visible clinical symptoms against a lethal dose of influenza virus. These data confirm that Advax is a potent mucosal adjuvant that boosts vaccine-induced humoral and cellular immune responses both in the lung and systemically with major positive effects on B-cell memory and complete protection against live virus. Hence, respiratory tract immunization, particularly via the lungs, with Advax-adjuvanted WIV formulation as a liquid or dry powder is a promising alternative to parenteral influenza vaccination.",
keywords = "Whole inactivated influenza vaccine, Mucosal, Advax, Inhalation, Powders, Immune mechanisms, Protection, DELTA INULIN ADJUVANT, POLYSACCHARIDE ADJUVANT, IMMUNE-RESPONSES, PULMONARY IMMUNIZATION, MEMORY, DELIVERY, IMMUNOGENICITY, VACCINES, GENERATION, ANTIBODIES",
author = "Jasmine Tomar and Patil, {Harshad P.} and Gustavo Bracho and Tonnis, {Wouter F.} and Frijlink, {Henderik W.} and Nikolai Petrovsky and Rita Vanbever and Anke Huckriede and Hinrichs, {Wouter L. J.}",
year = "2018",
month = "10",
day = "28",
doi = "10.1016/j.jconrel.2018.09.006",
language = "English",
volume = "288",
pages = "199--211",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier Bedrijfsinformatie b.v.",

}

RIS

TY - JOUR

T1 - Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge

AU - Tomar, Jasmine

AU - Patil, Harshad P.

AU - Bracho, Gustavo

AU - Tonnis, Wouter F.

AU - Frijlink, Henderik W.

AU - Petrovsky, Nikolai

AU - Vanbever, Rita

AU - Huckriede, Anke

AU - Hinrichs, Wouter L. J.

PY - 2018/10/28

Y1 - 2018/10/28

N2 - Administration of influenza vaccines via the respiratory tract has potential benefits over conventional parenteral administration, inducing immunity directly at the site of influenza exposure as well as being needle free. In this study, we investigated the suitability of Advax (TM), a stable particulate polymorph of inulin, also referred to as delta inulin, as a mucosal adjuvant for whole inactivated influenza vaccine (WIV) administered either as a liquid or dry powder formulation. Spray freeze-drying produced Advax-adjuvanted WIV powder particles in a size range (1-5 mu m) suitable for inhalation. The physical and biological characteristics of both WIV and Advax remained unaltered both by admixing WIV with Advax and by spray freeze drying. Upon intranasal or pulmonary immunization, both liquid and dry powder formulations containing Advax induced significantly higher systemic, mucosal and cellular immune responses than non-adjuvanted WIV formulations. Furthermore, pulmonary immunization with Advax-adjuvanted WIV led to robust memory B cell responses along with an increase of lung localization factors i.e. CXCR3, CD69, and CD103. A less pronounced but still positive effect of Advax was seen on memory T cell responses. In contrast to animals immunized with WIV alone, all animals pulmonary immunized with a single dose of Advax-adjuvanted WIV were fully protected with no visible clinical symptoms against a lethal dose of influenza virus. These data confirm that Advax is a potent mucosal adjuvant that boosts vaccine-induced humoral and cellular immune responses both in the lung and systemically with major positive effects on B-cell memory and complete protection against live virus. Hence, respiratory tract immunization, particularly via the lungs, with Advax-adjuvanted WIV formulation as a liquid or dry powder is a promising alternative to parenteral influenza vaccination.

AB - Administration of influenza vaccines via the respiratory tract has potential benefits over conventional parenteral administration, inducing immunity directly at the site of influenza exposure as well as being needle free. In this study, we investigated the suitability of Advax (TM), a stable particulate polymorph of inulin, also referred to as delta inulin, as a mucosal adjuvant for whole inactivated influenza vaccine (WIV) administered either as a liquid or dry powder formulation. Spray freeze-drying produced Advax-adjuvanted WIV powder particles in a size range (1-5 mu m) suitable for inhalation. The physical and biological characteristics of both WIV and Advax remained unaltered both by admixing WIV with Advax and by spray freeze drying. Upon intranasal or pulmonary immunization, both liquid and dry powder formulations containing Advax induced significantly higher systemic, mucosal and cellular immune responses than non-adjuvanted WIV formulations. Furthermore, pulmonary immunization with Advax-adjuvanted WIV led to robust memory B cell responses along with an increase of lung localization factors i.e. CXCR3, CD69, and CD103. A less pronounced but still positive effect of Advax was seen on memory T cell responses. In contrast to animals immunized with WIV alone, all animals pulmonary immunized with a single dose of Advax-adjuvanted WIV were fully protected with no visible clinical symptoms against a lethal dose of influenza virus. These data confirm that Advax is a potent mucosal adjuvant that boosts vaccine-induced humoral and cellular immune responses both in the lung and systemically with major positive effects on B-cell memory and complete protection against live virus. Hence, respiratory tract immunization, particularly via the lungs, with Advax-adjuvanted WIV formulation as a liquid or dry powder is a promising alternative to parenteral influenza vaccination.

KW - Whole inactivated influenza vaccine

KW - Mucosal

KW - Advax

KW - Inhalation

KW - Powders

KW - Immune mechanisms

KW - Protection

KW - DELTA INULIN ADJUVANT

KW - POLYSACCHARIDE ADJUVANT

KW - IMMUNE-RESPONSES

KW - PULMONARY IMMUNIZATION

KW - MEMORY

KW - DELIVERY

KW - IMMUNOGENICITY

KW - VACCINES

KW - GENERATION

KW - ANTIBODIES

U2 - 10.1016/j.jconrel.2018.09.006

DO - 10.1016/j.jconrel.2018.09.006

M3 - Article

VL - 288

SP - 199

EP - 211

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -

ID: 66157619